A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04440735|
Recruitment Status : Recruiting
First Posted : June 22, 2020
Last Update Posted : May 26, 2021
Part 1: A first-in-human, open-label, Phase I dose escalation study of DSP107 monotherapy and combination therapy with atezolizumab in patients with advanced solid tumors.
Part 2: Preliminary efficacy assessment of DSP107 single agent treatment and DSP107 in combination with atezolizumab in second line treatment of non small cell lung cancer
|Condition or disease||Intervention/treatment||Phase|
|Advanced Solid Tumor Non Small Cell Lung Cancer||Biological: DSP107 Biological: Atezolizumab||Phase 1 Phase 2|
This study will be the first time that DSP107 is administered to human subjects. The aim of the study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of DSP107 monotherapy and combination therapy in a two-part design.
Part 1 will involve DSP107 monotherapy dose escalation in subjects with advanced solid tumors that are not amenable to surgical resection or other approved therapeutic options that have demonstrated clinical benefit. Additional dose finding cohorts will be enrolled to establish a safe dose of DSP107 when given in combination with atezolizumab.
Part 2 will comprise a single expansion cohort consisting of two treatment arms in which subjects will be treated either with DSP107 monotherapy or DSP107 in combination with atezolizumab. This part of the study will enrol subjects with non small cell lung cancer who have progressed following first line treatment with PD-1 or PD-L1 targeting agents having previously achieved a best response of stable disease or better.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Sequential Assignment|
|Intervention Model Description:||
Part 1 will involve sequential enrolment of patient cohorts to investigate the safety of up to 7 potential dose levels. Dose escalation will commence with up to 3 single subject cohorts before moving to a 3 + 3 dose escalation scheme to determine the maximum tolerated dose and/or recommended phase II dose.
Up to 3 additional dose finding cohorts will be enrolled in parallel to the monotherapy dose escalation to establish a safe dose of DSP107 when given in combination with atezolizumab. These dose-finding combination arms will start at least one dose level below a DSP107 monotherapy dose that has already been deemed safe.
Part 2 information will be updated on completion of Part 1.
|Masking:||None (Open Label)|
|Official Title:||Phase I/II Study of DSP107 in Subjects With Advanced Solid Tumors Including a Dose-escalation Safety Study (Part 1) and Preliminary Efficacy Assessment of DSP107 as Monotherapy and in Combination With Atezolizumab (Part 2)|
|Actual Study Start Date :||October 7, 2020|
|Estimated Primary Completion Date :||June 2023|
|Estimated Study Completion Date :||August 2023|
Experimental: DSP107 monotherapy
DSP107 will be administered by intravenous infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle. The study will include up to 12 treatment cycles. Starting dose will be 0.01 mg/kg and maximum dose will not exceed 10 mg/kg.
DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
Experimental: DSP107 in combination with atezolizumab
DSP107 will be administered by IV infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle. Subjects will receive atezolizumab 1200 mg by intravenous infusion over 30 mins (first infusion over 1 hour) on Day 1 of every treatment cycle. DSP107 infusion will commence 1 hour following completion of atezolizumab infusion.
DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1
- Adverse Events (AEs) [ Time Frame: Duration of the study, estimated to be 9 months ]An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
- Dose Limiting Toxicities (DLT) [ Time Frame: At the end of Treatment Cycle 1 (each cycle is 21 days) ]A DLT is defined as a clinically significant AE of laboratory abnormality that is related to DSP107 or the combination of DSP107 and atezolizumab, but is unrelated to disease progression, intercurrent illness or concomitant medications
- DSP107 Serum Concentration [ Time Frame: At the end of Treatment Cycle 8 (each cycle is 21 days) ]Serum samples will be collected to determine circulating levels and PK profile of DSP107
- DSP107 Effect on Phenotypic and Activation Profiles of Peripheral Blood Mononuclear Cells [ Time Frame: At the end of Treatment Cycle 8 (each cycle is 21 days) ]Blood samples will be collected and examined by flow cytometry to determine the effect of DSP107 on different T-cells, B-cells, NK cells and monocytes, and their expression of activation markers.
- DSP107 and atezolizumab anti-drug antibody (ADA) formation [ Time Frame: Duration of the study, estimated to be 9 months ]Serum samples will be collected throughout the study for assessment of ADA formation using validated assay.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04440735
|Contact: Yaffa Shwartzfirstname.lastname@example.org|
|Contact: Adam Foley-Comer, MDemail@example.com|
|United States, California|
|Moores Cancer Center, UCSD||Not yet recruiting|
|La Jolla, California, United States, 92093|
|Contact: Ashley Weaver 858-822-1962 firstname.lastname@example.org|
|Principal Investigator: Sandip Patel, MD|
|United States, Colorado|
|University of Colorado Hospital, Anschutz Cancer Pavilion (ACP)||Recruiting|
|Aurora, Colorado, United States, 80045|
|Contact: Aaron Parsons, BS, MS 720-848-4603 email@example.com|
|Principal Investigator: Antonio Jimeno, MD|
|United States, Kansas|
|KUCC / KUMCRI University of Kansas Cancer Center||Recruiting|
|Kansas City, Kansas, United States, 66204|
|Contact: Lanecia Wright 913-588-4769 firstname.lastname@example.org|
|Contact: Tina Liu email@example.com|
|Principal Investigator: Anwaar Saeed, MD|
|United States, Pennsylvania|
|SKCC-Sidney Kimmel Cancer Center Thomas Jefferson University||Recruiting|
|Philadelphia, Pennsylvania, United States, 19107|
|Contact: Tina Savio 215-955-6407 Tina.Savio@Jefferson.edu|
|Contact: Aliya Rogers Aliya.Rogers@jefferson.edu|
|Principal Investigator: Babar Bashir, MD|
|UPMC Hillman Cancer Center University of Pittsburgh||Recruiting|
|Pittsburgh, Pennsylvania, United States, 15232|
|Contact: Sarah Brodeur 412-623-2944 firstname.lastname@example.org|
|Contact: Mallory Reed email@example.com|
|Principal Investigator: Luke Jason, MD|
|Principal Investigator:||Jason Luke, MD||University of Pittsburgh|